文献速递糖尿病

使用Hypo-RESOLVE队列的低血糖风险因素与预测:对胰岛素临床试验汇总数据的二次分析

Risk factors and prediction of hypoglycaemia using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials.
PubMed 文献 · Diabetologia · 2024-05-25

Hypo-RESOLVE项目汇总90项试验、46254例1型或2型糖尿病患者数据,分别分析低血糖相关因素并评估预测模型。女性、白人、糖尿病病程长、使用人胰岛素而非仅类似物胰岛素、血糖变异性高、基线6周低血糖评分高、血压和血脂较低及使用精神药物与低血糖更频繁相关。6周低血糖事件和血糖监测可预测未来低血糖风险,1型糖尿病中预测1级或更差低血糖的AUC为0.835(95%CI 0.826,0.844),2型糖尿病为0.840(95%CI 0.831,0.848)。

要点

  • 汇总90项试验、46254例1型或2型糖尿病患者,分析低血糖相关因素及预测。
  • 预测任何严重程度低血糖优于预测需要帮助的低血糖(3级低血糖)。
  • 1型糖尿病预测1级或更差低血糖AUC 0.835(95%CI 0.826,0.844),2型糖尿病AUC 0.840(95%CI 0.831,0.848)。

核心结论

  • 尽管低血糖发生率随社会人口学、临床特征和治疗史呈现很大变化,但观察6周低血糖事件和血糖测量可预测未来低血糖风险。

研究设计与样本

  • Hypo-RESOLVE项目汇总来自制药和设备公司的1型或2型糖尿病临床试验数据,共90项试验、46254例参与者,分别对1型和2型糖尿病进行分析。
  • 使用泊松混合模型(校正年龄、性别、糖尿病病程和试验标识)评估临床变量与低血糖事件计数的关联。
  • 使用训练数据拟合基于树的梯度提升算法(XGBoost),在测试数据上以受试者工作特征曲线下面积(AUC)评估预测性能。
  • 比较基线模型(含年龄、性别和糖尿病病程)、进一步纳入研究入组后前6周低血糖评分的模型以及纳入更多临床变量的完整模型,并使用XGBoost重要性程序评估各协变量的相对预测重要性。
  • 评估每项试验整个试验期间的预测,1型糖尿病平均34.8周,2型糖尿病平均25.3周。

主要发现

  • 在1型和2型糖尿病中,与更频繁低血糖相关的变量包括女性、白人、糖尿病病程更长、使用人胰岛素而非仅类似物胰岛素、血糖变异性更高、6周基线期低血糖评分更高、血压更低、血脂更低以及使用精神药物。
  • 预测任何严重程度的任何低血糖事件优于预测需要帮助的低血糖(3级低血糖),后者事件更稀疏。
  • 预测整个随访期间1级或更差低血糖,1型糖尿病AUC为0.835(95%CI 0.826,0.844),2型糖尿病AUC为0.840(95%CI 0.831,0.848)。
  • 预测3级低血糖,1型糖尿病AUC较低为0.689(95%CI 0.667,0.712),2型糖尿病为0.705(95%CI 0.662,0.748)。
  • 与基线模型相比,预测的改善几乎均可由个体低血糖史、血糖变异性和6周基线期血糖捕捉。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The objective of the Hypoglycaemia REdefining SOLutions for better liVES (Hypo-RESOLVE) project is to use a dataset of pooled clinical trials across pharmaceutical and device companies in people with type 1 or type 2 diabetes to examine factors associated with incident hypoglycaemia events and to quantify the prediction of these events. METHODS: Data from 90 trials with 46,254 participants were pooled. Analyses were done for type 1 and type 2 diabetes separately. Poisson mixed models, adjusted for age, sex, diabetes duration and trial identifier were fitted to assess the association of clinical variables with hypoglycaemia event counts. Tree-based gradient-boosting algorithms (XGBoost) were fitted using training data and their predictive performance in terms of area under the receiver operating characteristic curve (AUC) evaluated on test data. Baseline models including age, sex and diabetes duration were compared with models that further included a score of hypoglycaemia in the first 6 weeks from study entry, and full models that included further clinical variables. The relative predictive importance of each covariate was assessed using XGBoost's importance procedure. Prediction across the entire trial duration for each trial (mean of 34.8 weeks for type 1 diabetes and 25.3 weeks for type 2 diabetes) was assessed. RESULTS: For both type 1 and type 2 diabetes, variables associated with more frequent hypoglycaemia included female sex, white ethnicity, longer diabetes duration, treatment with human as opposed to analogue-only insulin, higher glucose variability, higher score for hypoglycaemia across the 6 week baseline period, lower BP, lower lipid levels and treatment with psychoactive drugs. Prediction of any hypoglycaemia event of any severity was greater than prediction of hypoglycaemia requiring assistance (level 3 hypoglycaemia), for which events were sparser. For prediction of level 1 or worse hypoglycaemia during the whole follow-up period, the AUC was 0.835 (95% CI 0.826, 0.844) in type 1 diabetes and 0.840 (95% CI 0.831, 0.848) in type 2 diabetes. For level 3 hypoglycaemia, the AUC was lower at 0.689 (95% CI 0.667, 0.712) for type 1 diabetes and 0.705 (95% CI 0.662, 0.748) for type 2 diabetes. Compared with the baseline models, almost all the improvement in prediction could be captured by the individual's hypoglycaemia history, glucose variability and blood glucose over a 6 week baseline period. CONCLUSIONS/INTERPRETATION: Although hypoglycaemia rates show large variation according to sociodemographic and clinical characteristics and treatment history, looking at a 6 week period of hypoglycaemia events and glucose measurements predicts future hypoglycaemia risk.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Mellor J, Kuznetsov D, Heller S, et al. Risk factors and prediction of hypoglycaemia using the Hypo-RESOLVE cohort: a secondary analysis of pooled data from insulin clinical trials. Diabetologia. 2024. PMID: 38795153. doi:10.1007/s00125-024-06177-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。